Uchida Toshihiro, Wada Hideo, Mizutani Minoru, Iwashita Miho, Ishihara Hiroaki, Shibano Toshiro, Suzuki Misako, Matsubara Yumiko, Soejima Kenji, Matsumoto Masanori, Fujimura Yoshihiro, Ikeda Yasuo, Murata Mitsuru
New Product Laboratories II, Daiichi Pharmaceutical, Tokyo, Japan.
Blood. 2004 Oct 1;104(7):2081-3. doi: 10.1182/blood-2004-02-0715. Epub 2004 May 4.
Congenital thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) is associated with an inherited von Willebrand factor-cleaving protease (ADAMTS13 [a disintegrin and metalloprotease with thrombospondin type I domains 13]) deficiency. In this study, we identified novel mutations in the ADAMTS13 gene in a patient with TTP. The patient was a 51-year-old Japanese male who exhibited TTP symptoms at frequent intervals. The ADAMTS13 activity during acute episodes was less than 3% that of normal. The enzyme activities of the patient's father and mother were both 46%, and both parents were asymptomatic. Genetic analysis revealed that the patient was a compound heterozygote for 2 mutations. One mutation was a missense mutation in the metalloprotease domain (A250V, exon 7), and the other was a guanine to adenine substitution at the 5' end of intron 3 (intron 3 G-->A). In vitro expression studies revealed that the A250V mutation markedly reduced ADAMTS13 activity and the intron 3 G-->A mutation caused abnormal mRNA synthesis.
先天性血栓性血小板减少性紫癜/溶血尿毒综合征(TTP/HUS)与遗传性血管性血友病因子裂解蛋白酶(ADAMTS13 [含I型血小板反应蛋白结构域的去整合素和金属蛋白酶13])缺乏有关。在本研究中,我们在一名TTP患者中鉴定出ADAMTS13基因的新突变。该患者为一名51岁的日本男性,频繁出现TTP症状。急性发作期间ADAMTS13活性低于正常水平的3%。患者父母的酶活性均为46%,且父母均无症状。基因分析显示该患者为两个突变的复合杂合子。一个突变是金属蛋白酶结构域中的错义突变(A250V,第7外显子),另一个是第3内含子5'端的鸟嘌呤到腺嘌呤替换(内含子3 G→A)。体外表达研究表明,A250V突变显著降低了ADAMTS13活性,而内含子3 G→A突变导致异常mRNA合成。